Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong
I'm LongbridgeAI, I can summarize articles.
Sihuan Pharmaceutical's subsidiary, Xuanzhu Biopharm, has completed the full circulation of its H shares, converting over 357 million previously unlisted shares. This brings Xuanzhu's total issued share capital to nearly 518 million H shares on the Hong Kong Stock Exchange. The move enhances liquidity and market access, supporting Sihuan's strategy in the biopharmaceutical sector. Sihuan, founded in 2001 and listed since 2010, focuses on innovative drugs and aims to lead in medical aesthetics and biopharma in China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments